Scientists issue warning after detecting shift in rare predator's hunting habits: 'Likely to happen to humans too'
Land development and habitat loss have driven fishing cats in Thailand to near extinction, per Mongabay. To survive, they've been living closer to humans. But how has that affected their species?
What's happening?
The International Union for Conservation of Nature has marked fishing cats as vulnerable to extinction, according to Mongabay.
Traditionally, fishing cats have lived and hunted in marshlands. However, human activity has forced them out of their natural habitats. They've consequently turned to agricultural and aquacultural developments for stable food sources, like fish, rodents, and insects.
Unfortunately, they've also eaten people's chickens, leading to a hostile relationship with local farmers, who have killed them in retaliation. Conservationists are trying to change the narrative, pointing out fishing cats' affinity for pest control.
While this has helped prevent violence against the cats, the species still has low genetic diversity. And that's not all — scientists have also discovered microplastics in their bodies.
"Fishing cats and people occupy the same ecological role of top predator," Rattapan Pattanarangsan, a program manager at a wild cat conservation organization, told Mongabay. "So, what happens to fishing cats is likely to happen to humans too."
Why does the fishing cat's decline matter?
As far as humans are concerned, take a look at fishing cats' diets. The discovery of microplastics in their digestive systems doesn't bode well for ours. Studies have found that microplastics are the most abundant pollutants in the oceans, being consumed by fish and making their way up the food chain to top predators.
Research indicates that microplastics have huge health consequences, damaging your kidneys, heart, and reproductive system. So far, no one knows exactly what this is doing to fishing cats. But it doesn't bode well.
Like Pattanarangsan said, fishing cats are apex predators. This is a crucial role in any ecosystem. When apex predators die out, prey populations spiral out of control.
Let's use another apex predator as an example. According to BBC Wildlife, the hunting of grey wolves at Yellowstone National Park set off a chain reaction: elk populations increased, overgrazed on trees, and caused the local beaver population's sharp decline.
Do you think we should be trying to pull pollution out of the atmosphere?
Absolutely
I need to know more
In some situations
No way
Click your choice to see results and speak your mind.
The fishing cats are no different. Like all animals, they're part of a complex, delicate web. When a species goes extinct, it can have dire consequences for another.
What's being done about it?
In Thailand, fishing cats are becoming a kind of national mascot.
Teacher Supoj Sukapat is leading youth conservation initiatives in which students learn about marshlands and the importance of fishing cats. He told Mongabay that kids are going home and telling their parents not to harm the cats.
Killing fishing cats is also a no-go in Thailand, and those who break the law are subject to heavy fines and/or imprisonment.
If you'd like to help the fishing cats on an individual level, consider donating to causes that directly work with wild cats.
Other takeaways from this story include the importance of discussing environmental issues with your family and friends and doing what you can to limit plastic pollution.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Bracco Imaging Receives Regulatory Approval in China for SonoVue® in the Assessment of Fallopian Tube Patency
New indication of SonoVue® supports non-invasive assessment of female infertility through contrast-enhanced ultrasound in China MILAN, Aug. 6, 2025 /PRNewswire/ -- Bracco Imaging, a global leader in diagnostic imaging, today announced that its ultrasound contrast agent SonoVue® has been approved by the China's National Medical Products Administration (NMPA) for use in hysterosalpingo contrast sonography (HyCoSy). HyCoSy is a contrast-enhanced ultrasound (CEUS) procedure that helps identifying potential causes of female infertility related to blockage of the fallopian tubes or uterine abnormalities with a high level of diagnostic accuracy (1,2). Fallopian tube conditions, such as blockages, scarring, or other damage, are a leading cause of infertility, contributing to approximately 25–35 percent of cases of infertility among women in China (3). This regulatory approval represents an important milestone in the management of infertility because, unlike laparoscopic assessment of tubal patency with use of a dye, HyCoSy is a non-invasive procedure, and, unlike traditional X-ray hysterosalpingography, HyCosy does not expose to radiation the genital tract of women in their reproductive years (4-6). "The NMPA approval of SonoVue® use with HyCoSy marks an important step in expanding access to non-invasive, radiation-free detection of tubal issues and uterine problems that often cause infertility in women," said Alberto Spinazzi, Chief Medical and Regulatory Officer, Bracco Group. "We strive to provide healthcare professionals in China with solutions that advance standards of care, reflecting our commitment to advancing diagnostic precision and improving the patient experience through contrast-enhanced ultrasound." "We are proud to support China's healthcare priorities through solutions like SonoVue® that may help address important diagnostic needs," said Valtero Canepa, Head of APAC, Bracco Imaging. "This new indication advances Bracco's role in delivering meaningful innovation in support of the Healthy China 2030 initiative, which prioritizes earlier detection, clinical precision, and broader access to reproductive health services." The high diagnostic performance of HyCoSy with SonoVue® has been confirmed by a recent systematic review and meta-analysis of 24 clinical studies (total of 1358 women with infertility and 2661 fallopian tubes). Using laparoscopic chromotubation dye test as the standard of truth for the assessment of fallopian tube patency, the pooled estimates of sensitivity, specificity, and accuracy of HyCoSy with SonoVue® were 93%, 90%, and 96%, respectively (1). Backed by over 20 years of clinical use, SonoVue® is the ultrasound contrast agent with the largest number of approved indications in the largest number of countries worldwide. The newly approved HyCoSy indication reinforces Bracco Imaging's commitment to expanding non-invasive, high-quality diagnostic tools aligned with evolving clinical standards and national health objectives in China and beyond. Qu E, Zhang M, Ju J, Chen Y, Lin X, Zhang X. Is Hysterosalpingo-Contrast Sonography (HyCoSy) Using Sulfur Hexafluoride Microbubbles (SonoVue) Sufficient for the Assessment of Fallopian Tube Patency? A Systematic Review and Meta-Analysis. J Ultrasound Med 2023; 42:7-15 Wang T, Dong T, Nie F. Clinical applications, advances, and future directions in hysterosalpingography. Front Med 2025; 12:1537506 Reproductive Health Branch of Chinese Preventive Medicine Association. Chinese Expert Consensus on Holistic Management of Tubal Factor Infertility (2023 edition) [J]. Chinese Journal of Practical Gynecology and Obstetrics 2023; 39:318-324 Roy KK, Gajapathy SR, Rai R, Zangmo R, Das A, Singhal S. Assessment of Tubal Patency with Selective Chromopertubation at Office Hysteroscopy versus Modified Minilaparoscopy in Infertile Women. Gynecol Minim Invasive Ther 2021; 10:159-165 Perisinakis K, Damilakis J, Grammatikakis J, Theocharopoulos N, Gourtsoyiannis N. Radiogenic risks from hysterosalpingography. Eur Radiol 2003; 13:1522-1528 Sulieman A, Theodorou K, Vlychou M, Topaltzikis T, Roundas C, Fezoulidis I, Kappas C. Radiation dose optimisation and risk estimation to patients and staff during hysterosalpingography. Radiat Prot Dosimetry 2008;128:217-226 For additional information about Bracco's products, and for full prescribing information, please visit About Bracco ImagingBracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Bracco Imaging has 3,800 employees and operates in more than 100 markets globally. Bracco Imaging has a well skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. Discover Bracco at Media Contacts: Bracco Press Contact:Carolina BargoniBracco Imaging, Communications 347 5397738 SOURCE Bracco Imaging
Yahoo
3 hours ago
- Yahoo
When does the body really start aging? The answer may surprise you.
When does aging really shift into overdrive? A new study suggests it may be sooner than you think. Scientists at the Chinese Academy of Sciences studied proteins in tissue taken from about 70 people ages 14 to 68, according to the study published July 25 in the journal Cell. These proteins give scientists a window of when the aging process may begin on a cellular level, said Dr. Thomas Blackwell, associate dean for graduate medical education and professor of medicine at the University of Texas Medical Branch. Proteins are created in a 'factory' using instructions from messenger RNA, he said. A sign of aging is when the cells' ability to make proteins correctly and efficiently starts to break down. By looking at tissues taken from organs throughout the body, including the heart, liver, pancreas, spleen, lung, skin and muscles, researchers determined that aging starts to accelerate from 45 to 55. They also found that organs aged at different rates. For example, the spleen, aorta (the body's main artery) and adrenal gland (responsible for producing hormones) showed signs of aging at around 30. The aorta also saw the biggest changes in protein levels around the ages of 45 and 55. 'This is just a beautiful roadmap that gives us an initial overview of organ aging,' said Neville Sanjana, associate professor of biology, neuroscience and physiology at New York University and a faculty member at the New York Genome Center. The study's findings could have a lot of implications in future research into treatments for chronic conditions related to aging that would not only add decades to patients' lifespan, but also their health span, which is the period of a person's life spent in good health, he said. 'To me, that's exciting,' Sanjana said. 'This kind of data generation is so powerful for folks who want to do things like bioengineering and creating new kinds of therapies to restore healthy aging.' For Blackwell, the study also shows that patients still have the chance to change their aging trajectory later in life – 'but the window is short,' he said. The best ways to add healthy years to your life are to maintain a healthy level of blood pressure, blood sugar and cholesterol, don't smoke and drink "very little," Blackwell said. Research has shown diet, exercise, genetics and, sometimes, luck, impact longevity. However, the new study suggests people may still see benefits from changes later in life. 'Starting at 45 to 50, you could gain as much as 10 years of healthy life and this study just shows the truth of that at a cellular level,' he said. Adrianna Rodriguez can be reached at adrodriguez@ This article originally appeared on USA TODAY: Aging: Body starts changing after 50. Here's what happens. Solve the daily Crossword
Yahoo
7 hours ago
- Yahoo
JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio's DEX-G2 Blood Test For Early Detection of Gastric Cancer
SAN ANTONIO, Aug. 5, 2025 /PRNewswire/ -- A groundbreaking multicenter clinical study published on July 30 in JAMA Surgery confirms the powerful diagnostic performance of the Destinex assay, a novel liquid biopsy that serves as the foundation for Cizzle Bio's DEX-G2 blood-based assay for early detection of gastric cancer—one of the world's deadliest malignancies. The study's findings validate the clinical utility of DEX-G2 as a minimally invasive, clinically actionable tool to detect gastric cancer at its earliest and most treatable stages, when timely intervention can significantly improve outcomes and save lives. The DESTINEX study, conducted at leading cancer centers in Japan and South Korea, evaluated a signature panel of microRNAs derived from exosomes and cell-free serum. The study analyzed 809 serum specimens from 480 participants, including patients with gastric cancer and matched controls. Using machine learning to refine and validate the assay, researchers demonstrated exceptional diagnostic accuracy for early-stage gastric cancer. The study was led by Ajay Goel, Ph.D., AGAF, an internationally recognized leader in cancer biomarker research and the developer of the Destinex assay. Goel also serves as scientific advisor to Cizzle Bio and is chair of the Department of Diagnostics and Experimental Therapeutics at City of Hope Comprehensive Cancer Center, where he led the development of the Destinex assay into the DEX-G2 blood test that Cizzle Bio is now advancing for near-term commercial launch. "The publication of this study in JAMA Surgery is a critical milestone, not only for our scientific team but also for the future of early gastric cancer detection," said Goel. "By combining the sensitivity of cell-free microRNAs with the specificity of exosomal markers, Destinex—and now DEX-G2—offers a minimally invasive, accessible, and highly accurate method for detecting gastric cancer at a stage when outcomes can be dramatically improved." In the study, the Destinex assay achieved an area under the curve (AUC) of 96.8% in the validation cohort, with a sensitivity of 95.0% for detecting early-stage (pT1) gastric cancer. These findings underscore the assay's strength as a minimally invasive tool for identifying gastric cancer early when it is most curable. The assay achieved high sensitivity and specificity in distinguishing individuals with gastric cancer from those without the disease, confirming its potential not only as a minimally invasive screening tool but also to significantly improve patient outcomes through earlier detection and intervention. A Pressing Clinical Need Gastric cancer is the third leading cause of cancer-related deaths worldwide, mainly due to delayed diagnosis. Globally, more than 60% of gastric cancer cases are diagnosed at advanced stages, when curative treatment is no longer an option and prognosis is poor. Endoscopic screening has helped reduce mortality in high-incidence countries such as Japan and Korea, but its cost, invasiveness, and limited availability make it impractical for widespread use in low-incidence regions. Minimally invasive blood-based tests like DEX-G2 have the potential to fill this gap. The Destinex assay, the scientific basis of DEX-G2, demonstrated outstanding sensitivity and specificity for detecting early-stage (T1) gastric cancer, and its diagnostic performance remained robust across tumor stages and patient subgroups. The study also showed a significant drop in biomarker levels after surgical tumor removal, confirming the assay's tumor specificity. Read the full JAMA Surgery study here: "This study reinforces the scientific credibility and clinical utility of the technology behind DEX-G2," said Bill Behnke, CEO of Cizzle Bio. "We are proud to advance this innovation into clinical practice, where it has the potential to make earlier detection a reality for patients who currently have few options for early detection." From Discovery to Clinical Application Cizzle Bio is advancing its DEX-G2 test, based on the Destinex assay, for near-term commercial deployment in CLIA-certified laboratories. It is intended to support clinicians in detecting gastric cancer earlier, particularly in primary care and gastroenterology settings where endoscopy may not be accessible or practical. The company holds a worldwide exclusive license for DEX-G2 and is actively pursuing commercialization in both U.S. and global markets, with a focus on reaching populations where gastric cancer is often diagnosed too late for curative treatment. About Cizzle Bio Cizzle Bio is a Texas-based biotechnology company dedicated to revolutionizing cancer diagnostics by advancing biomarker-based blood tests, starting with early detection of lung and gastric cancers. Our goal is to empower patients, equip clinicians, and improve outcomes through innovation, compassion, and life-saving solutions. We hold exclusive licensing rights for our groundbreaking CIZ1B biomarker test in the United States, Canada, and the Caribbean and a worldwide exclusive license for our DEX-G2 biomarker gastric cancer test. Cizzle Bio is commercializing both tests for U.S. clinical Media Contact: Yolanda Heibergeryolanda@ View original content to download multimedia: SOURCE Cizzle Bio